An antithrombin III test measures a natural anticoagulant protein that keeps your blood from clotting too easily. Doctors usually order this test after an unexplained or recurrent blood clot, or before starting certain treatments, to check whether your body’s built-in clotting brake is working normally. This article explains what antithrombin III does, how to read your result against the reference range, what a low or high level can mean, and when the finding calls for a specialist. You will also find a plain-language look at how antithrombin relates to heparin treatment in the hospital, a glossary of the terms used here, and answers to common patient questions.
Mikä on antitrombiini III?
Antithrombin III, usually just called antithrombin, is a protein made mainly by your liver and released into the bloodstream. Its job is to act as a brake on clotting. Blood needs to clot to stop bleeding after an injury, but that process has to switch off again once the job is done — otherwise clots could keep growing inside healthy blood vessels.
Antithrombin does this by binding to and inactivating two key clotting enzymes, thrombin and factor Xa. Once antithrombin latches onto them, they can no longer drive the clotting cascade forward. This is a continuous, low-level process that keeps your blood flowing smoothly through normal, undamaged vessels.
Why antithrombin matters for heparin therapy
Antithrombin has a second, clinically important role: it is the target of heparin, a fast-acting blood-thinning medicine used in hospitals for surgery, dialysis, and treating existing clots. Heparin does not directly block clotting factors; instead, it binds antithrombin and speeds up its action by roughly a thousandfold. This means heparin can only work as well as the antithrombin available in your blood. If antithrombin levels are very low, heparin may not thin the blood as expected, a situation clinicians call heparin resistance.
Why your doctor may order this test
An antithrombin test is not part of routine bloodwork. It is typically requested when there is a specific reason to suspect a clotting-balance problem.
Common reasons include an unprovoked deep vein thrombosis or pulmonary embolism, especially in someone under 45; a strong family history of blood clots; recurrent clots despite standard risk factors being ruled out; unexplained pregnancy loss; or in a hospital setting, when a patient needs unusually high doses of heparin to reach a safe level of anticoagulation. The test is one part of a broader thrombophilia workup, which usually also checks protein C, proteiini S -taso, ja perinnölliset hyytymismutaatiot.
Myös ajoituksella on merkitystä. Koska raskaus, akuutit veritulppatapahtumat ja tietyt lääkkeet voivat kaikki tilapäisesti muuttaa antitrombiinin tasoja, lääkärit suosivat usein testin tekemistä näiden tilanteiden ulkopuolella, kun se on mahdollista – tai tulkitsevat niiden aikana saadun tuloksen erityisen varovaisesti. Jos ensimmäinen testisi tehdään akuutin sairauden aikana tai pian uuden veritulpan jälkeen, lääkärisi saattaa suositella uusintamittausta myöhemmin, akuutin vaiheen mentyä ohi, jotta nähdään tavallisempi lähtötasosi.
Kuinka lukea antitrombiini III -testituloksesi
Laboratorioraporttisi näyttää tuloksesi prosentteina normaalista aktiivisuudesta, ja sen rinnalla saattaa olla erillinen antigeeni- (proteiinimäärä) mittaus. Tyypillinen aikuisen viitearvo antitrombiinin aktiivisuudelle on noin 80–120 %, vaikka tarkat raja-arvot vaihtelevat hieman laboratorion ja testausmenetelmän mukaan.
| Tulosluokka | Likimääräinen viitealue | General meaning |
|---|---|---|
| Normaali | Noin 80–120 % | Antikoagulanttitoiminta on odotetulla tasolla |
| Lievästi matala | Noin 60–80 % | Voi viitata osittaiseen puutokseen tai tilapäiseen hankittuun syyhyn |
| Kohtalaisesti tai merkittävästi matala | Alle 60 % | Viittaa selvempään puutostilaan, joka usein edellyttää erikoislääkärin seurantaa |
| Korkea | Yli 120 % | Yleensä tilapäinen löydös, jolla on rajallinen kliininen merkitys |
Vertaa aina omaa tulostasi oman laboratorioraporttisi viitearvoihin yleisten lukujen sijaan, sillä menetelmät vaihtelevat laboratorioiden välillä. Yksittäinen poikkeava arvo on lähtökohta keskustelulle lääkärisi kanssa – ei itsessään diagnoosi.
Aktiivisuus- vs. antigeenimittaus
Jotkut laboratoriot ilmoittavat antitrombiinista kaksi erillistä arvoa: aktiivisuuden ja antigeenin. Aktiivisuustesti mittaa, kuinka hyvin proteiini toimii käytännössä, kun taas antigeeenitesti mittaa proteiinin määrää riippumatta siitä, toimiiko se oikein. Näiden kahden vertailu auttaa erottamaan määrään liittyvän ongelman laadullisesta ongelmasta, mikä on tärkeää perimmäisen syyn selvittämiseksi.
Matalan antitrombiini III:n ymmärtäminen: syyt ja tyypit
Viitearvon alittava tulos on paljon yleisempi kuin kohonnut arvo, ja lääkärit jakavat syyt perinnöllisiin ja hankittuihin.
Perinnöllinen antitrombiinin puutos
Perinnöllinen antitrombiinin puutos johtuu mutaatiosta SERPINC1-geenissä, ja sen arvioidaan esiintyvän noin yhdellä 2 000–3 000 ihmisestä. Se periytyy autosomaalisesti dominantisti, eli puutostilaa sairastavan vanhemman lapsella on noin 50 %:n todennäköisyys periä mutaatio. Tyypin I puutostilassa rakenteellisesti normaalia proteiinia on vähemmän, kun taas tyypin II puutostilassa proteiinia tuotetaan normaalisti, mutta se ei toimi kunnolla. Kummassakin tapauksessa veren antikoagulanttinen kapasiteetti heikkenee, mikä lisää ensimmäisen veritulpan elinikäistä riskiä – usein syvä laskimotukos tai keuhkoembolia ilmaantuu ennen 45 vuoden ikää.
Hankittu antitrombiinin puutos
Hankittu puutos kehittyy myöhemmin elämässä jonkin muun sairauden – ei geenimuutoksen – seurauksena. Yleisiä syitä ovat maksasairaus, munuaisten kautta tapahtuva proteiinihukka sekä kuluminen akuutin sairauden aikana, kuten alla on kuvattu.
| Syy | Miksi antitrombiini laskee |
|---|---|
| Vaikea maksasairaus | Maksa tuottaa antitrombiinia, joten pitkälle edennyt maksasairaus heikentää sen tuotantoa; aiheeseen liittyviä merkkiaineita käsitellään maksan toimintakokeiden oppaassamme |
| Nefroottinen oireyhtymä | Tässä munuaistilassa elimistö menettää antitrombiinia suoraan virtsaan – aihetta käsitellään munuaisten toimintapaneelin yleiskatsauksessamme |
| Disseminoitunut intravaskulaarinen koagulaatio (DIC) | Widespread clotting activation rapidly consumes antithrombin along with other clotting factors |
| Prolonged heparin therapy | Extended heparin use can gradually lower antithrombin through increased consumption |
| Major surgery or acute illness | Vakava sairaus ja suuret leikkaukset voivat tilapäisesti laskea tasoja |
High antithrombin III levels: what an elevated result means
Viitearvon ylittävä antitrombiiniarvo on harvinainen, eikä sillä yleensä ole yhtä suurta kliinistä merkitystä kuin puutoksella. Se voi esiintyä estrogeenia sisältävän hormonihoidon aikana, akuutin maksatulehduksen varhaisvaiheessa tai raskauden ensimmäisellä kolmanneksella. Nämä kohonneet arvot ovat yleensä tilapäisiä ja palautuvat tavallisesti itsestään, kun taustalla oleva syy on poistunut.
Antitrombiini III, hepariiniresistenssi ja sairaalahoito
Koska hepariini tarvitsee antitrombiinia toimiakseen, matalat antitrombiiniarvot voivat heikentää tavanomaisten hepariiniannosten tehoa – erityisesti sydänleikkauksissa, joissa käytetään sydän-keuhkokonetta, tai kriittisesti sairailla potilailla, jotka saavat pitkäkestoista hepariini-infuusiota. Kun potilas tarvitsee poikkeuksellisen suuria hepariiniannoksia turvallisen hyytymisajan saavuttamiseksi, hoitotiimi saattaa tarkistaa antitrombiiniaktiivisuuden osana selvittelyä muiden mahdollisten syiden ohella. Hoitovaihtoehtoja voivat olla suurempi hepariiniannos, antitrombiinikorvaushoito, tuore pakastettu plasma tai siirtyminen antikoagulanttiin, joka ei ole riippuvainen antitrombiinista, kuten suoraan trombiinin estäjään.
Päätöksenteon tueksi: mitä tuloksesi jälkeen yleensä tapahtuu
| Tilanteesi | Yhteinen seuraava askel |
|---|---|
| Normal result, no symptoms | No specific follow-up needed for this marker alone |
| Mildly low, no prior clot, no family history | Often monitored; precautions considered around surgery, pregnancy, or immobility |
| Low result with a personal history of a blood clot | Referral to a hematologist for a full thrombophilia evaluation |
| Low result found through family screening | Genetic counseling and individualized risk discussion, often without automatic anticoagulant therapy |
| Low result during a hospital stay, on heparin | Reassessed by the treating team, since acute illness can transiently lower levels |
Milloin mennä lääkäriin
Ota yhteyttä terveydenhuollon ammattilaiseen viipymättä, jos sinulla on poikkeava antitrombiiniarvo yhdistettynä johonkin seuraavista, sillä ne voivat olla merkkejä aktiivisesta veritulpasta:
- Sudden swelling, pain, warmth, or redness in one leg, which can suggest a deep vein thrombosis or related clotting event
- Unexplained shortness of breath, chest pain that worsens with breathing, or coughing up blood
- Perheenjäsenellä on äskettäin todettu perinnöllinen hyytymishäiriö
- Plans for surgery, pregnancy, or starting hormonal contraception with a known or suspected deficiency
These symptoms need urgent medical evaluation regardless of when your last blood test was done, since a laboratory result only reflects a single point in time.
Living with an antithrombin deficiency: practical steps
If you have a confirmed deficiency, your care plan will depend on its severity and your personal history. General measures that support healthy circulation include staying well hydrated, avoiding long periods of immobility during travel or after surgery, maintaining a healthy weight, and not smoking, since tobacco use promotes clot formation. Anyone with a known deficiency should tell every new healthcare provider about the diagnosis before a procedure, since perioperative planning may need adjustment. None of these lifestyle steps replace anticoagulant therapy when it is prescribed; they work alongside your doctor’s plan, not instead of it.
Pregnancy deserves special mention, since it is one of the highest-risk periods for someone with a known deficiency. Pregnancy itself naturally shifts the body toward more clotting to prepare for delivery, and this effect can compound an existing deficiency. Many women with a confirmed hereditary deficiency receive preventive blood-thinning injections during pregnancy and for several weeks after delivery, with the exact plan set by a hematologist working alongside an obstetrician. If you know you have a deficiency and are planning a pregnancy, raising this early, ideally before conception, gives your care team time to prepare a monitoring and prevention plan.
Family members are also part of the picture. Because hereditary deficiency follows a predictable inheritance pattern, first-degree relatives, meaning parents, siblings, and children, of someone diagnosed with the condition may be offered testing themselves, particularly if they are considering surgery, pregnancy, or hormonal contraception. A relative who tests positive but has never had a clot is not automatically started on long-term anticoagulant therapy; instead, the focus is usually on targeted prevention during known higher-risk periods.
Uusimmat tieteelliset edistysaskeleet
According to PubMed, the American Society of Hematology published updated evidence-based guidelines in 2023 on thrombophilia testing, including antithrombin, protein C, and protein S deficiency (Middeldorp et al., Blood Advances, 2023; DOI-koodi). The panel found that broad population screening before starting birth control is not helpful, but recommended targeted testing in specific situations, such as a family history of antithrombin deficiency when someone is weighing hormone therapy or thromboprophylaxis. In plain terms, this confirms that antithrombin testing works best when aimed at people with a real reason for suspicion, rather than as a general screening tool.
A 2024 systematic review and meta-analysis pooled data from more than 107,000 people to quantify how much hereditary thrombophilia types actually raise clotting risk (Alnor et al., Annals of Hematology, 2024; DOI-koodi). It found that antithrombin deficiency carries an intermediate level of risk compared with other inherited clotting disorders — meaningfully elevated, but somewhat lower than earlier, smaller studies had suggested. For readers, this is a reassuring nuance: a deficiency raises risk, but the size of that risk may be more modest than older estimates implied, which is one reason your doctor weighs your personal and family history alongside the lab result rather than treating every deficiency identically.
A 2025 systematic review conducted for the CDC examined thrombosis risk when women with an inherited clotting tendency, including antithrombin deficiency, use hormonal contraception (Tepper et al., Contraception, 2025; DOI-koodi). It found that estrogen-containing birth control appeared to further raise clotting risk in women who already have a thrombophilia, while evidence on progestin-only methods remained more limited. What this means for you: if you carry a known deficiency and are considering contraception, this is a conversation worth having with your doctor, since non-estrogen options are generally considered safer in this context — though the certainty of the underlying evidence is still described as low, meaning more research is expected to refine this guidance.
On the hospital side, a 2025 study of 605 cardiac surgery patients directly tested whether low antithrombin activity explains heparin resistance during bypass surgery (Kim et al., Journal of Cardiothoracic and Vascular Anesthesia, 2025; DOI-koodi). Surprisingly, preoperative antithrombin activity was not significantly associated with heparin resistance in this group; active infection and aortic surgery were the stronger risk factors instead. This is an early but well-designed finding that nuances a longstanding assumption — it suggests that in some surgical settings, low antithrombin may be a less important explanation for heparin resistance than previously believed, and that routinely giving antithrombin concentrate to prevent it may not always be necessary. This remains a single study, and practice may continue to vary between hospitals as more research accumulates.
Separately, a 2023 study from Johns Hopkins looked at acquired antithrombin deficiency in children supported on extracorporeal membrane oxygenation (ECMO), a heart-lung support machine (Procaccini et al., British Journal of Clinical Pharmacology, 2023; DOI-koodi). Deficiency was common in this critically ill population, and about a third of measurements stayed low even after antithrombin replacement. For families of children on ECMO, this underscores that antithrombin monitoring in intensive care is an evolving area, with dosing strategies still being refined rather than fully standardized.
Sanasto
| Termi | Määritelmä |
|---|---|
| Antithrombin (antithrombin III) | A liver-made protein that inhibits thrombin and factor Xa to prevent excessive blood clotting |
| Trombofiilia | An increased tendency of the blood to form clots, whether inherited or acquired |
| Trombiini | A central clotting enzyme that converts fibrinogen into fibrin, the mesh that forms a clot |
| Factor Xa | A clotting enzyme that helps activate thrombin; a key target of antithrombin and some anticoagulant drugs |
| Heparin resistance | A reduced response to standard heparin doses, sometimes linked to low antithrombin activity |
| SERPINC1 gene | The gene that provides instructions for producing antithrombin; mutations here cause hereditary deficiency |
| Disseminoitunut intravaskulaarinen koagulaatio (DIC) | A serious condition where widespread clotting activation consumes clotting factors, sometimes causing bleeding and clotting together |
| Nefroottinen oireyhtymä | A kidney disorder causing significant protein loss in the urine, which can include antithrombin |
| Autosomal dominant inheritance | A genetic pattern where one copy of a mutated gene from either parent is enough to potentially cause the condition |
Usein kysytyt kysymykset
What is a dangerously low antithrombin III level?
There is no single universal cutoff for “dangerous,” because risk depends on the whole clinical picture, not just the number. That said, activity levels below roughly 60% are generally taken more seriously by clinicians, especially alongside a personal or family history of clotting. Severe deficiency, along with acute triggers like surgery or pregnancy, raises concern further. Your hematologist interprets your specific value together with your symptoms and history rather than applying one fixed threshold to everyone.
Can antithrombin III levels be improved naturally?
Diet and lifestyle cannot correct a genetic deficiency, since the underlying gene mutation remains unchanged. However, general habits that support healthy circulation, such as staying active, avoiding prolonged immobility, not smoking, and maintaining a healthy weight, can help reduce your overall clotting risk. If a low level is caused by an acquired condition like liver disease, treating that underlying condition may allow antithrombin levels to recover over time.
Is antithrombin III the same as antithrombin?
Yes. The protein was originally named antithrombin III when several numbered antithrombin activities were described decades ago, but “antithrombin” is now the standard scientific name for the same protein. You may see either term used interchangeably on lab reports, in medical literature, and by your doctor.
Does antithrombin III deficiency cause symptoms on its own?
Typically, no. Most people with a deficiency have no symptoms until a blood clot actually forms, which is why the condition is often discovered only after a first thrombosis or through family screening once a relative is diagnosed. This is an important reason doctors take an unexplained clot in a younger person seriously enough to investigate underlying causes.
How often should antithrombin III be retested?
There is no universal schedule, since retesting depends on why the test was ordered in the first place. A single mildly abnormal result in someone without symptoms may simply be discussed at a future visit, while a confirmed deficiency with a history of clotting often prompts more structured, periodic monitoring by a hematologist. Your doctor will set a personalized follow-up plan based on your situation.
Can medications affect my antithrombin III test result?
Yes. Heparin use, especially prolonged use, can lower measured antithrombin activity due to increased consumption, while estrogen-containing medications can raise it. Because of this, it is important to tell the laboratory and your doctor about every medication you are taking, including hormonal contraception, so your result can be interpreted in the right context rather than assumed to reflect your baseline level.
Antithrombin III sits at the center of your body’s natural clot-control system, working alongside markers like aPTT, protein C, ja D-dimeeri to give doctors a fuller picture of your coagulation health. Understanding what these values mean can help you follow a preventive plan more confidently and ask more focused questions at your next appointment. AI DiagMe is built to help you make sense of results like these — it explains what your numbers show in plain language, without diagnosing you or replacing the care of your physician.
Ymmärrä laboratoriotuloksiasi tekoälyn DiagMen avulla
Tulkitse tuloksesi muutamassa minuutissa
Lähteet
- Antithrombin III Injection — Cleveland Clinic
- Hereditary Antithrombin Deficiency — MedlinePlus Genetics, U.S. National Library of Medicine (NIH)
- Deep Vein Thrombosis (DVT): Symptoms & Causes — Mayo Clinic
- Middeldorp et al., American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing — Blood Advances, 2023 (PubMed)
- Alnor et al., Venous Thromboembolism Risk in Adults with Hereditary Thrombophilia: A Systematic Review and Meta-Analysis — Annals of Hematology, 2024 (PubMed)
- Tepper et al., Thrombosis Risk with the Use of Hormonal Contraception Among Women with Thrombophilia: An Updated Systematic Review — Contraception, 2025 (PubMed)
- Kim et al., Analysis of Risk Factors for Heparin Resistance During Cardiac Surgery: Does Antithrombin Deficiency Cause Heparin Resistance? — Journal of Cardiothoracic and Vascular Anesthesia, 2025 (PubMed)
- Procaccini et al., Evaluation of Acquired Antithrombin Deficiency in Paediatric Patients Supported on Extracorporeal Membrane Oxygenation — British Journal of Clinical Pharmacology, 2023 (PubMed)
Lisälukemista
- Koagulaatiopaneelin selitys: PT, PTT, INR ja D-dimeeri
- Proteiini C: Täydellinen opas verikokeen ymmärtämiseen
- Proteiini S -testin tulokset: Tasojesi ja niiden merkityksen ymmärtäminen
- K-vitamiini: Ymmärrä tulokset ja toimi niiden perusteella
- Blood work before surgery: What tests are done and why
